MondegarAI
Euclidean Capital LLC

Q4 2024 · 13F-HR

Euclidean Capital LLCholdings as filed

Filed 2025-02-14 · accession 0001012975-25-000088

$736.7M
Reported value
11
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
78462F103SPYSPDR S&P 500 ETF TR$525.3M71.3%896,254CommonSOLE
46429B598INDAISHARES TR$127.7M17.3%2,425,144CommonSOLE
922042775VEUVANGUARD INTL EQUITY INDEX F$58.2M7.90%1,013,434CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$8.0M1.08%989,410CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$7.4M1.01%1,573,761CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$4.0M0.54%2,627,643CommonSOLE
014442107ALECALECTOR INC$2.5M0.34%1,307,858CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$1.5M0.20%1,015,705CommonSOLE
86889P208SRZNSURROZEN INC$1.3M0.17%87,696CommonSOLE
75382E109RAPT THERAPEUTICS INC$1.0M0.14%657,899CommonSOLE
86889P117SRZNWSURROZEN INC$3,6560.00%170,833CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.